share_log

Arcutis Biotherapeutics | 3: Initial statement of beneficial ownership of securities-Officer Topper David Joseph

Arcutis Biotherapeutics | 3: Initial statement of beneficial ownership of securities

Arcutis Biotherapeutics | 3：首次持股聲明
SEC announcement ·  04/11 20:36
Moomoo AI 已提取核心訊息
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.
根據表格3，Arcutis Biotherapeutics首席財務官大衛·約瑟夫·託珀已向美國證券交易委員會提交了初步的證券實益所有權聲明。這份日期爲2024年4月10日的文件顯示，Topper以實益方式擁有非衍生證券，並已將股票期權授予該公司。具體而言，Topper有權以每股2.54美元的行使價購買7,500股普通股，該期權的行使期權有效期至2033年12月18日。該表格由託珀的實務律師松田正於2024年4月11日簽署。根據1934年《證券交易法》第16（a）條，該文件是公司高管在報告其持有的公司證券時要求的例行披露。
根據表格3，Arcutis Biotherapeutics首席財務官大衛·約瑟夫·託珀已向美國證券交易委員會提交了初步的證券實益所有權聲明。這份日期爲2024年4月10日的文件顯示，Topper以實益方式擁有非衍生證券，並已將股票期權授予該公司。具體而言，Topper有權以每股2.54美元的行使價購買7,500股普通股，該期權的行使期權有效期至2033年12月18日。該表格由託珀的實務律師松田正於2024年4月11日簽署。根據1934年《證券交易法》第16（a）條，該文件是公司高管在報告其持有的公司證券時要求的例行披露。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息